<DOC>
	<DOCNO>NCT00389805</DOCNO>
	<brief_summary>RATIONALE : Bortezomib pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . Giving bortezomib together pemetrexed disodium may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose two different schedule bortezomib give together pemetrexed disodium see well work treat patient advance non-small cell lung cancer solid tumor .</brief_summary>
	<brief_title>Bortezomib Pemetrexed Disodium Treating Patients With Advanced Non-Small Cell Lung Cancer Other Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety , include dose-limiting toxicity , feasibility combine bortezomib pemetrexed disodium patient advance non-small cell lung cancer ( NSCLC ) solid tumor . ( Phase I ) - Determine response rate patient advance NSCLC treat regimen . ( Phase II ) Secondary - Compare toxicity 2 different schedule bortezomib pemetrexed disodium patient advance solid tumor . ( Phase I ) - Determine maximum tolerate dose ( MTD ) bortezomib administer pemetrexed disodium 2 different treatment schedule patient . ( Phase I ) - Determine , preliminarily , efficacy combination bortezomib pemetrexed disodium patient advance solid tumor . ( Phase I ) - Assess overall survival progression-free survival patient . ( Phase II ) - Evaluate frequency severity toxicity associate regimen . ( Phase II ) Tertiary - Perform laboratory correlative study tumor tissue blood sample investigate potential predictor response . ( Phase II ) OUTLINE : This phase I , dose-escalation study bortezomib follow phase II , open-label study . - Phase I : Patients accrue , alternate fashion , 1 2 treatment group . - Group I : Patients receive pemetrexed disodium IV day 1 bortezomib IV day 1 , 4 , 8 , 11 . - Group II : Patients receive pemetrexed disodium IV day 1 bortezomib IV day 1 8 . In group , treatment repeat every 21 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient per group receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive pemetrexed disodium bortezomib ( MTD ) either group I group II phase I portion study . Selection treatment schedule base upon observed toxicity , safety , tolerability , efficacy , clinical practicality . Blood drawn baseline prior course 2 3 correlative molecular study . Tumor tissue blood sample patient enrol phase II portion study examine various biological marker . Immunohistochemistry used measure BCL-2 gene , BCL-xL gene , BAX gene , p27 . Reverse transcriptase-polymerase chain reaction use assay expression thymidylate synthase , folsyl-polyglutamate synthase , reduce folate carrier . Levels plasminogen-activator inhibitor 1 gene , vascular endothelial growth factor , osteopontin measure immunoenzyme technique . The nuclear expression NF-kB p27 blood compare study treatment flow cytometry . After completion study treatment , patient phase I follow 30 day patient phase II follow periodically . PROJECTED ACCRUAL : A total 86 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically histologically confirm diagnosis 1 following : Advanced solid tumor progress standard therapy effective curative therapy exists ( phase I ) Stage IIIB ( pleural effusion ) IV nonsmall cell lung cancer ( NSCLC ) ( phase II ) Disease must progress recur 1 platinumbased therapy regimen NSCLC progress recurred firstline therapy stage IIIA IIIB disease allow Measurable disease Disease previously irradiate site consider measurable clear disease progression follow radiotherapy Evaluable disease ( bone metastasis , pleural fluid , ascites ) allow ( phase I ) No symptomatic brain metastasis disease require steroid anticonvulsant Asymptomatic , previously treat ( surgical resection radiotherapy ) brain metastasis allow provided patient neurologically stable steroid anticonvulsant ≥ 4 week PATIENT CHARACTERISTICS : Zubrod performance status 02 ( phase I ) 01 ( phase II ) Life expectancy ≥ 3 month Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min Bilirubin normal AST ≤ 2.5 time upper limit normal Granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No preexisting neuropathy ≥ grade 2 No prior malignancy except follow ( phase II ) : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat stage I II cancer currently complete remission Any cancer patient disease free &gt; 5 year No hypersensitivity bortezomib , boron , mannitol No cardiovascular complication , include follow : Myocardial infarction within past 6 month New York Heart Association class IIIIV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmia Electrocardiographic ( ECG ) evidence acute ischemia active conduction system abnormalities Any ECG abnormality screen must document medically relevant PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior bortezomib pemetrexed disodium Any number prior chemotherapy regimen allow ( phase I ) More 4 week since prior chemotherapy ( 6 week mitomycin C ) recover More 2 week since prior radiotherapy recover No nonsteroidal antiinflammatory drug ( NSAIDs ) salicylates 2 day prior 2 day ( 5 day pre post longacting NSAIDs ) administration pemetrexed disodium No concurrent anticonvulsant metabolize cytochrome P450 pathway , include follow : Enzymeinducing drug Primidone Carbamazepine Phenobarbital Phenytoin Enzymeinhibiting drug Oxcarbazepine Topiramate Zonisamide Valproic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>